

Christophe Hirtz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10645474/publications.pdf>

Version: 2024-02-01

67
papers

1,790
citations

346980

22
h-index

355658

38
g-index

70
all docs

70
docs citations

70
times ranked

3493
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 1-18.	2.7	14
2	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
3	Changes Occurring on the Activity of Salivary Alpha-Amylase Proteoforms in Two Naturalistic Situations Using a Spectrophotometric Assay. <i>Biology</i> , 2021, 10, 227.	1.3	5
4	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. <i>International Journal of Legal Medicine</i> , 2021, 135, 2081-2089.	1.2	7
5	Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection. <i>Immunologic Research</i> , 2021, 69, 255-263.	1.3	5
6	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
7	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1605-1618.	2.3	8
8	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. <i>Bioanalysis</i> , 2021, 13, 1029-1035.	0.6	6
9	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 2291-2299.	1.3	7
10	Variation of human salivary alpha-amylase proteoforms in three stimulation models. <i>Clinical Oral Investigations</i> , 2020, 24, 475-486.	1.4	7
11	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	2.7	24
12	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	3.0	33
13	Hepcidin and ferritin levels in restless legs syndrome: a case-control study. <i>Scientific Reports</i> , 2020, 10, 11914.	1.6	21
14	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	1.2	9
15	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. <i>Neuroscience</i> , 2020, 441, 142-160.	1.1	9
16	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 26.	3.0	138
17	Soluble Intercellular Adhesion Molecule- (sICAM-) 1, Thrombospondin-1, and Vinculin for the Identification of Septic Shock Patients Suffering from an Invasive Fungal Infection. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	1.4	2
18	Efficient extraction of intact HSA-A β peptide complexes from sera: Toward albuminome biomarker identification. <i>Talanta</i> , 2020, 216, 121002.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Peripheral Blood and Salivary Biomarkers of Bloodâ€”Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. <i>Frontiers in Neurology</i> , 2020, 11, 577312.	1.1	36
20	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. <i>Analytical Chemistry</i> , 2019, 91, 15500-15508.	3.2	6
21	SILK studies â€” capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	4.9	37
22	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 173-190.	0.7	0
23	Biochemical markers of time since death in cerebrospinal fluid: A first step towardsâ€”Forensomicsâ€”. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 274-286.	2.7	8
24	Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. <i>BMJ Open</i> , 2019, 9, e025129.	0.8	17
25	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , 2019, 1959, 163-172.	0.4	0
26	The prognostic value of theÂ”Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. <i>BMC Cancer</i> , 2019, 19, 110.	1.1	20
27	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 110-117.	1.2	6
28	Association between serum hepcidin level and restless legs syndrome. <i>Movement Disorders</i> , 2018, 33, 618-627.	2.2	25
29	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. <i>Bioanalysis</i> , 2018, 10, 35-45.	0.6	12
30	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. <i>Data in Brief</i> , 2018, 18, 1013-1021.	0.5	12
31	Towards a routine application of Top-Down approaches for label-free discovery workflows. <i>Journal of Proteomics</i> , 2018, 175, 12-26.	1.2	17
32	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Topâ€”Down Proteomics: A Pilot Study. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 477.	1.4	20
33	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. <i>Bioanalysis</i> , 2018, 10, 1383-1399.	0.6	5
34	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	4.9	140
35	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. <i>Bioanalysis</i> , 2018, 10, 723-735.	0.6	12
36	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 346-358.	2.7	9

#	ARTICLE	IF	CITATIONS
37	Alzheimer's Disease: Advances in Drug Development. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 3-13.	1.2	45
38	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. <i>Clinica Chimica Acta</i> , 2017, 467, 51-58.	0.5	29
39	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 465-469.	0.7	1
40	Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS/MS. <i>Bioanalysis</i> , 2017, 9, 337-347.	0.6	12
41	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. <i>Neurobiology of Aging</i> , 2017, 53, 59-66.	1.5	76
42	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2559-2567.	1.9	16
43	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 173-184.	2.7	19
44	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. <i>Bioanalysis</i> , 2017, 9, 427-434.	0.6	14
45	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2017, 36, 391-396.	0.6	9
46	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1291-1295.	1.2	16
47	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. <i>Scientific Reports</i> , 2016, 6, 25162.	1.6	36
48	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1033-1043.	1.2	104
49	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 759-764.	1.2	23
50	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. <i>Clinica Chimica Acta</i> , 2016, 454, 33-38.	0.5	19
51	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. <i>Bioanalysis</i> , 2016, 8, 43-53.	0.6	22
52	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. <i>Journal of Proteome Research</i> , 2016, 15, 667-676.	1.8	91
53	Stable Isotope Labeling by Amino acid <i>in Vivo</i> (SILAV): a new method to explore protein metabolism. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 1917-1925.	0.7	10
54	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. <i>Frontiers in Neuroscience</i> , 2015, 9, 302.	1.4	34

#	ARTICLE	IF	CITATIONS
55	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?. <i>Bioanalysis</i> , 2015, 7, 2849-2851.	0.6	1
56	Quantitative detection of amyloid- β peptides by mass spectrometry: state of the art and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1483-93.	1.4	30
57	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
58	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 649-55.	1.4	8
59	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. <i>EuPA Open Proteomics</i> , 2014, 3, 60-67.	2.5	19
60	Current and future use of "dried blood spot" analyses in clinical chemistry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1897-1909.	1.4	102
61	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 919-35.	1.4	47
62	From "Clinical Proteomics" to "Clinical Chemistry Proteomics": considerations using quantitative mass-spectrometry as a model approach. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 235-42.	1.4	7
63	Proteins and proteolysis in pre-term and term human milk and possible implications for infant formulae. <i>International Dairy Journal</i> , 2010, 20, 715-723.	1.5	56
64	Use of Reducing/Nonreducing Two-Dimensional Electrophoresis for the Study of Disulfide-Mediated Interactions between Proteins in Raw and Heated Bovine Milk. <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 5948-5955.	2.4	54
65	Proteomic Studies of Saliva: A Proposal for a Standardized Handling of Clinical Samples. <i>Clinical Proteomics</i> , 2007, 3, 13-21.	1.1	23
66	Salivary protein profiling in type I diabetes using two-dimensional electrophoresis and mass spectrometry. <i>Clinical Proteomics</i> , 2006, 2, 117-127.	1.1	18
67	MS characterization of multiple forms of alpha-amylase in human saliva. <i>Proteomics</i> , 2005, 5, 4597-4607.	1.3	70